Solid pseudopapillary and malignant pancreatic tumors in childhood: A systematic review and evidence quality assessment | Zendy

Mylonas Konstantinos S. | Zendy; Doulamis Ilias P. | Zendy; Tsilimigras Diamantis I. | Zendy; Nasioudis Dimitrios | Zendy; Schizas Dimitrios | Zendy; Masiakos Peter T. | Zendy; Kelleher Cassandra M. | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Solid pseudopapillary and malignant pancreatic tumors in childhood: A systematic review and evidence quality assessment

Author(s) -

Mylonas Konstantinos S.,

Doulamis Ilias P.,

Tsilimigras Diamantis I.,

Nasioudis Dimitrios,

Schizas Dimitrios,

Masiakos Peter T.,

Kelleher Cassandra M.

Publication year - 2018

Publication title -

pediatric blood and cancer

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.116

H-Index - 105

eISSN - 1545-5017

pISSN - 1545-5009

DOI - 10.1002/pbc.27114

Subject(s) - medicine , radiation therapy , neuroendocrine tumors , pancreaticoduodenectomy , chemotherapy , adjuvant radiotherapy , oncology , adjuvant chemotherapy , pancreas , cancer , breast cancer

A systematic review of 32 studies reporting on 489 children with pancreatic tumors was performed. The most prevalent histologic subtype was solid pseudopapillary tumor (SPT) (61.3%). Pancreaticoduodenectomy was the most commonly performed operation (48%). Neoadjuvant chemo/radiotherapy was utilized in 3.9, 36.2, 25, and 27.8% of patients with SPTs, pancreatoblastomas (PBLs), neuroendocrine tumors, and exocrine carcinomas, respectively. Adjuvant chemotherapy (75.6%) and radiation (34%) were most commonly utilized in PBLs. All‐cause mortality was highest in exocrine carcinomas (50%). Overall, 98.8% of patients with SPTs survived. PBL exhibited the highest recurrence rate (14.7%) within a mean of 23.5 months.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research